OBN (UK) Ltd
Paul Edwards MBE is an accomplished executive with extensive experience in the biotechnology and healthcare sectors. Currently serving as Executive Chairman of IsomAb since March 2022, Paul leads the development of isoform-specific monoclonal antibodies aimed at addressing unmet medical needs. As Managing Partner at SCi Partners, Paul has demonstrated a commitment to high growth in life sciences recruitment since 2011. In the role of Chairperson for OBN, Paul supports a membership organization that connects UK life sciences companies and investors. Paul's background includes pivotal roles at Imophoron Ltd, NanoMab Technology Ltd, Ruston Poole International, and various directorships with organizations such as Goldshield plc and Bio Products Laboratory. Notably, as CEO of GeneMedix, Paul played a critical role in pioneering biosimilar medicines, and at Genzyme, Paul contributed to substantial company growth during their tenure. Paul holds a Bachelor of Science degree in Chemistry from the University of Surrey.
OBN (UK) Ltd
OBN is the membership organisation supporting and bringing together the UK's emerging life science companies, corporate partners and investors. Our 450+ member companies are located across the Golden Triangle and beyond, and benefit from our networking, partnering, purchasing, advising, and advocacy activities. OBN organises BioTrinity - Europe's Leading Investment and Biopartnering Conference, find out more at www.biotrinity.com.